Dna X (SONM) Cash & Equivalents (2018 - 2026)

Dna X's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Cash & Equivalents fell 43.5% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 43.5% YoY) and the FY2025 annual result came in at $1.3 million, down 75.61% from the prior year.
• Cash & Equivalents was $1.2 million for Q1 2026 at Dna X, down from $1.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $15.5 million in Q3 2022 and bottomed at $281000.0 in Q2 2023.
• A 5-year average of $5.4 million and a median of $2.1 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 86.64% — and 2024, when it surged 3316.37%.
• Dna X's Cash & Equivalents stood at $1.5 million in 2022, then jumped by 526.05% to $9.4 million in 2023, then sank by 43.14% to $5.3 million in 2024, then plunged by 75.61% to $1.3 million in 2025, then dropped by 8.29% to $1.2 million in 2026.
• Business Quant data shows SONM's Cash & Equivalents at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $2.1 million in Q3 2025.